Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 8/20 | 0.33 |
| ▸ | CTSB | P07858 | 4/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467322 | 0.90 | KMT2A (0.33) | SMN1; SMN2 | |
| SCHEMBL7044233 | 0.85 | ATM (0.35) | ATMCTSLCTSBSMN1; SMN2ACACB | |
| SCHEMBL6463146 | 0.82 | ATM (0.32) | ATMCTSLCTSBSMN1; SMN2CTSS | |
| SCHEMBL7049041 | 0.79 | ATM (0.38) | ATM | |
| SCHEMBL7147621 | 0.76 | HDAC3 (0.45) | — | |
| SCHEMBL7046896 | 0.75 | CCR6 (0.33) | ATM | |
| SCHEMBL6350520 | 0.74 | TRPM8 (0.49) | ATMCTSLCTSBSMN1; SMN2CTSS | |
| SCHEMBL6467733 | 0.74 | ALDH1A1 (0.36) | SMN1; SMN2CTSS | |
| SCHEMBL7045317 | 0.74 | MEN1 (0.38) | SMN1; SMN2CTSK | |
| SCHEMBL7045360 | 0.74 | CYP3A4 (0.38) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | ATM 3419/4885CTSL 18/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.